Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Mayo Clin Proc ; 89(1): 43-51, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24388021

RESUMEN

OBJECTIVE: To determine if bisphosphonates are associated with reduced risk of acute myocardial infarction (AMI). PATIENTS AND METHODS: A cohort of 14,256 veterans 65 years or older with femoral or vertebral fractures was selected from national administrative databases operated by the US Department of Veterans Affairs and was derived from encounters at Veterans Affairs facilities between October 1, 1998, and September 30, 2006. The time to first AMI was assessed in relationship to bisphosphonate exposure as determined by records from the Pharmacy Benefits Management Database. Time to event analysis was performed using multivariate Cox proportional hazards regression. An adjusted survival analysis curve and a Kaplan-Meier survival curve were analyzed. RESULTS: After controlling for atherosclerotic cardiovascular disease risk factors and medications, bisphosphonate use was associated with an increased risk of incident AMI (hazard ratio, 1.38; 95% CI, 1.08-1.77; P=.01). The timing of AMI correlated closely with the timing of bisphosphonate therapy initiation. CONCLUSION: Our observations in this study conflict with our hypothesis that bisphosphonates have antiatherogenic effects. These findings may alter the risk-benefit ratio of bisphosphonate use for treatment of osteoporosis, especially in elderly men. However, further analysis and confirmation of these findings by prospective clinical trials is required.


Asunto(s)
Difosfonatos/efectos adversos , Fracturas del Fémur/epidemiología , Infarto del Miocardio/inducido químicamente , Infarto del Miocardio/epidemiología , Osteoporosis/tratamiento farmacológico , Osteoporosis/epidemiología , Fracturas de la Columna Vertebral/epidemiología , Factores de Edad , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/efectos adversos , Causalidad , Estudios de Cohortes , Comorbilidad , Bases de Datos Factuales/estadística & datos numéricos , Femenino , Fracturas del Fémur/tratamiento farmacológico , Humanos , Incidencia , Masculino , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Fracturas de la Columna Vertebral/tratamiento farmacológico , Análisis de Supervivencia , Estados Unidos/epidemiología , United States Department of Veterans Affairs/estadística & datos numéricos , Veteranos
2.
Phytother Res ; 28(6): 873-9, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24123556

RESUMEN

Black seed extracts are known to alter cellular metabolism through multiple signaling pathways. Since Forkhead box transcription factor 3 (FOXO3) has a significant role in regulating cellular metabolism, the effect of lipid extracts of black seed (Sativa nigella) on FOXO3 levels and AKT and 5-AMP activated protein kinase α (AMPKα) signaling was measured in HepG2 hepatoma cells. FOXO3 levels, phosphorylation, and nuclear exclusion were measured by Western blot, as were AKT and AMPK expression and activity using phosphorylation-specific antibodies. Apolipoprotein A-I expression, a black seed-responsive gene, was measured by Western blot. Treatment with black seed extract increased FOXO3 phosphorylation and decreased its expression. In contrast to control cells where FOXO3 was located primarily in the nucleus, in black seed-treated HepG2 cells, FOXO3 was localized primarily to the cytoplasm. These changes in FOXO3 phosphorylation, expression, and localization were accompanied by increased AKT activity. Black seed also decreased AMPKα activity but increased AMPKα expression. Lipid extracts from black seeds inhibit FOXO3 activity and thereby modulate the expression of FOXO3-dependent genes.


Asunto(s)
Factores de Transcripción Forkhead/metabolismo , Hepatocitos/efectos de los fármacos , Nigella sativa/química , Extractos Vegetales/farmacología , Proteínas Quinasas Activadas por AMP/metabolismo , Proteína Forkhead Box O3 , Células Hep G2 , Hepatocitos/metabolismo , Humanos , Fosforilación/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Semillas/química , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA